Orexo is a fully integrated specialty pharmaceutical company which has developed four products from idea to patient.
Products approved worldwide
Our drug delivery technologies improve pharmaceuticals
Partnerships are critical to our success
We will be recognized for the added value our products bring to patients and societies
Orexo’s share is listed on Nasdaq Stockholm Mid Cap and available as American Depository Receipts (ADRs) on OTCQX in the US.
Follow Orexo in social media
JUN 2 2017 Orexo receives USD 2.5 M milestone payment from AstraZeneca as OX-CLI advances into phase 1
Watch the video where CEO Nikolaj Sørensen presented at the Small Cap Day June 12, 2017. On the agenda – strategic priorities, pipeline and market/sales
Orexo has created a workspace with an open minded environment where new product ideas are captured from all across the organization.
Increased access to treatment and a strong growing public segment drives the growth
April 20, 2017 - "Zubsolv's growth in the US drives increased profitability"
Still much to do. #orexo. Opioids, a Mass Killer We’re Meeting With a Shrug https://t.co/GMcZL0Tff9
Good news. The Rezolv studie is now published in the Journal
of Addiction Medicine. #orexo #opioidaddiction
Stepping into the future - #orexo is now developing the next generation drug delivery technologies. Read more… https://t.co/zxBGZ7LmLk